公开(公告)号：US09611244B2

公开(公告)日：2017-04-04

申请号：US15148210

申请日：2016-05-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like.The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

公开(公告)号：US20210137962A9

公开(公告)日：2021-05-13

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Yoshitomi ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Yoshihisa Nakada ,  Michiyo Mochizuki

IPC: A61K31/7084 ,  A61P35/00 ,  A61K47/68 ,  A61K31/7076

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US09187453B2

公开(公告)日：2015-11-17

申请号：US14388452

申请日：2013-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tetsuya Tsukamoto ,  Yusuke Ohba ,  Takafumi Yukawa ,  Hiroyuki Nagamiya ,  Taku Kamei ,  Norihito Tokunaga ,  Morihisa Saitoh

IPC: C07D401/14 ,  C07D403/14 ,  A61K31/506 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D409/14 ,  C07D491/107

CPC classification number: C07D403/04 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/107

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10980825B2

公开(公告)日：2021-04-20

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Yoshihisa Nakada ,  Michiyo Mochizuki

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10787462B2

公开(公告)日：2020-09-29

申请号：US15769201

申请日：2016-10-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takatoshi Yogo ,  Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Katoh ,  Tomohiro Seki ,  Yoshihisa Nakada

IPC: C07D519/00 ,  C07D487/04 ,  C07D471/04 ,  C07D513/04 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P31/12 ,  A61P13/12 ,  A61P1/16 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like.The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20190192549A1

公开(公告)日：2019-06-27

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： MASATO YOSHIKAWA ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Yoshitomi ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20210106607A1

公开(公告)日：2021-04-15

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： MASATO YOSHIKAWA ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US09533966B2

公开(公告)日：2017-01-03

申请号：US15175292

申请日：2016-06-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro

IPC: C07D317/72

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Abstract translation: （其中，在说明书中更详细地说明每个符号）。

公开(公告)号：US20150094296A1

公开(公告)日：2015-04-02

申请号：US14388452

申请日：2013-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tetsuya Tsukamoto ,  Yusuke Ohba ,  Takafumi Yukawa ,  Hiroyuki Nagamiya ,  Taku Kamei ,  Norihito Tokunaga ,  Morihisa Saitoh ,  Atsutoshi Okabe

IPC: C07D403/04 ,  C07D401/14 ,  C07D413/14 ,  C07D491/107 ,  C07D403/14 ,  C07D405/14

CPC classification number: C07D403/04 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D491/107

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣，类风湿性关节炎，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮等）等，其具有优异的Tyk2 抑制作用。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US12171777B2

公开(公告)日：2024-12-24

申请号：US18310467

申请日：2023-05-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.